GLP-1 News & Updates
Daily summaries of the most important GLP-1 stories — FDA decisions, clinical research, telehealth updates, and insurance coverage changes.
Today — Thursday, April 30, 2026
4 articlesEli Lilly Reports Q1 2026 Earnings; Investors Watch Mounjaro, Zepbound, and Foundayo Trajectories
TLDR: Eli Lilly is releasing its first-quarter 2026 financial results pre-market on April 30, with a 10 a.m. ET conference call to follow. Wall Street is watching three GLP-1 storylines in particular: continued growth of Mounjaro and Zepbound (which together generated $36.5 billion in 2025 sales), gross-to-net pricing pressure on Zepbound, and management commentary on the rocky early launch of the new oral GLP-1 pill Foundayo (orforglipron) following weak IQVIA prescription data through April.
Read full story →Provocative New Paper Argues GLP-1 May Not Be Necessary for Effective Weight Loss
TLDR: Richard DiMarchi and Matthias Tschöp, two of the scientists whose work seeded the modern obesity-drug class, published a peer-reviewed paper proposing that activating only the GIP and glucagon receptors, with no GLP-1 component, can match GLP-1-containing drugs for weight loss in rodents and monkeys. Funded by BlueWater Biosciences, the experimental molecule reportedly avoids the nausea and vomiting common to current treatments. The findings are preclinical and have yet to be confirmed in humans.
Read full story →FormBlends Releases 2026 State of Peptides Report Mapping RFK-Era HHS Shifts on GLP-1 Access
TLDR: Telehealth platform FormBlends published its 2026 State of Peptides and GLP-1 Regulation report on April 28, charting how the Kennedy-led HHS, the FDA Center for Drug Evaluation and Research, and the obesity pipelines at Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access to weight-management and metabolic peptides. The 2026 HHS budget includes new language on "evidence review for therapeutic peptides," suggesting Category 2 designations on compounds like BPC-157, CJC-1295, and Sermorelin may be reassessed before 2027.
Read full story →APhA2026 Highlights GLP-1 Therapies Rewriting Metabolic Disease Care Across Specialties
TLDR: Coverage from the American Pharmacists Association 2026 annual meeting underscores how rapidly GLP-1 receptor agonists are crossing specialty lines, with new and expanded indications now spanning cardiovascular risk reduction, chronic kidney disease, MASH/liver fibrosis, and obstructive sleep apnea. Pharmacists at the meeting flagged growing complexity around adherence support, gross-to-net pricing changes, and patient counseling as the field shifts from injectables to a mixed oral-and-injectable landscape including oral Wegovy and Foundayo.
Read full story →Yesterday — Wednesday, April 29, 2026
4 articlesLilly's Foundayo Faces Weak Early Uptake as Q1 Earnings Loom This Week
TLDR: Early IQVIA prescription data shows Eli Lilly's new oral GLP-1 pill Foundayo (orforglipron) is significantly trailing Novo Nordisk's oral Wegovy in the weeks since its April 6 launch, sending LLY shares lower while NVO stock has climbed toward $41. Investors are watching Lilly's Q1 earnings report on April 30 for management commentary on the launch trajectory and any revised guidance on the oral obesity market.
Read full story →Novo Nordisk's Oral Semaglutide Hits Primary Endpoint in First Pediatric GLP-1 Trial
TLDR: Topline results from the Phase 3a PIONEER TEENS trial showed oral semaglutide delivered a statistically significant 0.83% greater HbA1c reduction versus placebo at week 26 in 132 children and adolescents aged 10 to 17 with type 2 diabetes. Novo Nordisk plans to file for pediatric label expansion in the U.S. and EU in the second half of 2026, which would make oral semaglutide the first oral GLP-1 receptor agonist approved for this population.
Read full story →FuturHealth Among First Telehealth Providers to Offer Lilly's Oral GLP-1 Foundayo
TLDR: Telehealth platform FuturHealth announced it is among the first providers to add Eli Lilly's newly approved oral GLP-1 Foundayo (orforglipron) to its weight-loss program offerings. The move expands non-injectable GLP-1 access beyond LillyDirect and signals the start of broader distribution through digital health channels as the pill's commercial launch ramps.
Read full story →GLP-1 Drugs Cut Heart and Kidney Risk in Type 1 Diabetes Patients, Johns Hopkins Finds
TLDR: A Johns Hopkins analysis of electronic health records from roughly 175,000 type 1 diabetes patients found that GLP-1 receptor agonists like semaglutide and tirzepatide reduced the five-year risk of major cardiovascular events by 15% and end-stage kidney disease by 19%. The findings strengthen the case for off-label use of GLP-1 therapies in type 1 diabetes, a population in which the drugs are not currently approved for cardiovascular or renal protection.
Read full story →Tuesday — Tuesday, April 28, 2026
4 articlesCMS Extends Medicare GLP-1 Bridge Through 2027, Delays BALANCE Obesity Model
TLDR: The Centers for Medicare & Medicaid Services announced it will extend the Medicare GLP-1 Bridge program — providing $50 monthly copays for Wegovy and Zepbound — through the end of 2027, while delaying the larger BALANCE model that had been scheduled to launch on January 1, 2027. The decision keeps a temporary access path open for eligible Medicare beneficiaries but pushes off the broader, permanent obesity-drug coverage framework.
Read full story →NEJM Analysis Warns GLP-1 Boom Could Surface 420,000 New Eating Disorder Cases
TLDR: A New England Journal of Medicine perspective published over the weekend estimates that if roughly one in eight Americans takes a GLP-1, more than 420,000 people could develop an eating disorder linked to the drugs. The authors urge prescribers to screen patients for disordered eating before starting Wegovy, Ozempic, or Zepbound and call for stronger clinical guardrails as use scales.
Read full story →23andMe Genetic Study Pinpoints Why GLP-1 Drugs Work Better — and Worse — in Some Patients
TLDR: Analyzing data from nearly 28,000 23andMe users on GLP-1 therapy, researchers identified a variant in the GLP1R gene that is significantly associated with greater weight loss, while carriers of certain other variants were 83% more likely to experience vomiting on tirzepatide. The findings could help explain why roughly one in ten patients respond poorly to these drugs and may inform future genetic screening before prescribing.
Read full story →Tirzepatide Linked to 62% Lower Death Risk in Heart Patients After PCI Procedures
TLDR: A new analysis of 1,281 patients who underwent percutaneous coronary intervention found a 62% lower mortality rate among those taking tirzepatide, the active ingredient in Mounjaro and Zepbound. The data add to a growing body of evidence — including the SUMMIT trial in heart failure with preserved ejection fraction — that tirzepatide's cardiovascular benefits may extend well beyond weight loss.
Read full story →Monday — Monday, April 27, 2026
4 articlesNovo Nordisk's Wegovy HD Now Available Nationwide at $399 Per Month
TLDR: Novo Nordisk announced that Wegovy HD, the higher-dose weekly semaglutide injection at 7.2 mg, is now available at all U.S. pharmacies and telehealth platforms for $399 per month. The shot delivered 20.7% mean weight loss in the STEP UP trial, with roughly one in three participants losing 25% or more of their body weight.
Read full story →Millions of Patients Are Losing Commercial Insurance Coverage for GLP-1 Weight-Loss Drugs
TLDR: An NPR investigation finds that roughly 12 million Americans each lost commercial insurance coverage for Wegovy and Zepbound between 2025 and 2026 as employers scaled back benefits due to high costs. The access gap is widening just months before Medicare is set to begin covering GLP-1s for obesity in July.
Read full story →GLP-1 Adherence Drops Sharply at Six Months in Real-World Medicaid Study
TLDR: A real-world study of Medicaid patients found that persistence with GLP-1 medications for obesity declined substantially within six months of starting treatment, with many patients stopping due to cost sharing, access barriers, and side effects. The findings raise concerns about whether coverage expansions alone will translate to durable health outcomes without stronger support structures.
Read full story →Major Nutrition and Obesity Societies Issue Joint Nutritional Guidelines for Patients on GLP-1 Therapy
TLDR: A joint advisory from four leading organizations — including the American Society for Nutrition and The Obesity Society — establishes nutritional priorities for people taking GLP-1 medications. The guidance recommends higher protein intake, routine micronutrient monitoring, and structured behavioral support to reduce the risk of muscle loss and nutritional deficiencies during treatment.
Read full story →Sunday — Sunday, April 26, 2026
4 articlesSimple Gut Reset Procedure May Stop Weight Gain After Stopping Ozempic or Wegovy
TLDR: Researchers found that a minimally invasive outpatient procedure called duodenal mucosal resurfacing may help people maintain weight loss after stopping GLP-1 drugs. The first blinded, randomized, sham-controlled trial showed it can prevent the rebound weight gain that affects roughly 70% of people who discontinue medications like Ozempic or Wegovy.
Read full story →Scientists Discover Why Ozempic Does Not Work for About 10% of Users
TLDR: A new study identified a genetic-based condition called GLP-1 resistance in roughly 10% of patients, explaining why some people see little benefit from semaglutide-based drugs. These individuals produce higher levels of the GLP-1 hormone naturally but do not respond to it properly, making standard dosing ineffective.
Read full story →Quitting a GLP-1 and Starting Again: What Patients and Doctors Need to Know
TLDR: Many patients are cycling on and off GLP-1 medications like Ozempic and Wegovy due to cost, side effects, or supply issues — a pattern doctors say carries real risks. Studies suggest stopping and restarting can accelerate fat regain while lean muscle loss accumulates over time, compounding metabolic harm.
Read full story →GLP-1 Access Is Tightening as FDA Enforcement Narrows Compounding Sources
TLDR: FDA enforcement actions against compounding pharmacies have significantly reduced the number of legal sources for compounded semaglutide and tirzepatide in 2026. Telehealth platforms are raising prices and patients who started treatment on compounded versions face fewer options as the market shifts toward brand-name medications.
Read full story →Saturday — Saturday, April 25, 2026
4 articlesTrump Administration Shelves Medicare GLP-1 Pilot, Will Fund Coverage Directly
TLDR: The Trump administration is indefinitely delaying its Medicare pilot program to cover weight-loss drugs after insurers raised cost concerns. Instead of requiring Part D plans to fund coverage, CMS will extend the GLP-1 Bridge program through 2027, giving eligible Medicare beneficiaries access to Wegovy and Zepbound at a $50/month copay paid by taxpayers.
Read full story →Novo Nordisk Oral Semaglutide Shows Promise for Teens With Type 2 Diabetes
TLDR: Novo Nordisk announced positive results from the PIONEER TEENS trial evaluating oral semaglutide in adolescents aged 10-17 with type 2 diabetes. The drug demonstrated superior HbA1c reduction versus placebo with an acceptable safety profile, and the company expects to file for regulatory label expansion in the US and EU in the second half of 2026.
Read full story →Minimally Invasive Gut Procedure May Help Prevent Weight Regain After Stopping GLP-1s
TLDR: Research presented at Digestive Disease Week 2026 suggests a minimally invasive outpatient gut procedure may help people avoid the significant weight regain that typically follows stopping GLP-1 medications. Around 70% of patients who discontinue drugs like Ozempic or Wegovy regain most of their lost weight within 18 months.
Read full story →Scientists Identify Genetic Reason Ozempic Does Not Work for About 10% of Users
TLDR: A new study found that roughly 10% of people have genetic variants that cause GLP-1 resistance, meaning their bodies produce elevated levels of the GLP-1 hormone but fail to respond to it normally. This discovery may explain why some patients see little to no weight loss or glycemic benefit from semaglutide-based drugs.
Read full story →Friday — Friday, April 24, 2026
5 articlesGLP-1 Price Deal Hits Snag as Medicare Delays Program Implementation
TLDR: The Trump administration reached Most-Favored-Nation pricing agreements with Eli Lilly and Novo Nordisk that would drop Wegovy and Zepbound to roughly $345-$350/month through TrumpRx and $245 for Medicare. However, a key piece of the deal fell apart this week when Medicare delayed implementing coverage for GLP-1s for obesity.
Read full story →Semaglutide Fails Two Large Alzheimer's Disease Trials
TLDR: Novo Nordisk reported that semaglutide showed no slowing of disease progression versus placebo in two large, randomized controlled trials in people with Alzheimer's disease. The disappointing results close off one of the most anticipated potential new uses of GLP-1 drugs beyond metabolic disease.
Read full story →Oral Semaglutide Shows Promise for Children and Teens with Type 2 Diabetes
TLDR: Novo Nordisk announced positive phase 3 results from the PIONEER TEENS trial, showing oral semaglutide significantly reduced blood sugar versus placebo in children and adolescents aged 10-17 with type 2 diabetes. The company plans to seek regulatory approval for a pediatric label expansion in the US and EU later this year.
Read full story →Gut Procedure May Prevent Weight Regain After Stopping GLP-1 Drugs
TLDR: A minimally invasive outpatient procedure called duodenal mucosal resurfacing may offer a lasting way to maintain weight loss after discontinuing GLP-1 medications. Researchers say the gut reset works by remodeling the intestinal lining, potentially addressing the root cause of weight regain that affects about 70% of patients who stop these drugs.
Read full story →Scientists Identify Why GLP-1 Drugs Do Not Work for About 10% of Users
TLDR: A new study found that specific genetic variants cause GLP-1 resistance in roughly 10% of people, explaining why some patients see little to no benefit from semaglutide and tirzepatide. These individuals naturally produce higher levels of the GLP-1 hormone but do not respond to it properly, pointing toward a need for personalized obesity treatment strategies.
Read full story →Thursday — Thursday, April 23, 2026
4 articlesStanford Scientists Discover Natural Molecule That Mimics GLP-1 Effect Without Nausea or Muscle Loss
TLDR: Stanford researchers identified a naturally occurring molecule called BRP that suppresses appetite by acting directly on brain regions controlling hunger, producing weight loss comparable to GLP-1 drugs in animal models but without nausea, vomiting, or muscle loss. The findings suggest a potential new class of obesity treatments that could benefit the subset of patients who discontinue GLP-1 therapy due to side effects.
Read full story →Pioneers of GLP-1 Drugs Propose Ditching the GLP-1 Receptor as a Target for Next-Generation Obesity Treatments
TLDR: Richard DiMarchi and Matthias Tschop, researchers whose work underpinned today's GLP-1 blockbusters, now argue that GLP-1 receptor activation may not be essential for effective obesity treatment. Their experimental compound targets GIP and glucagon receptors without a GLP-1 component and has shown equivalent weight loss in preclinical models with improved tolerability, potentially opening a new route for patients who cannot tolerate semaglutide or tirzepatide.
Read full story →GLP-1 Drugs Show Growing Promise Across Neurological Diseases, Despite Alzheimer Trial Setback
TLDR: A comprehensive review finds that while semaglutide failed to slow Alzheimer progression in the Phase 3 EVOKE trials, GLP-1 receptor agonists are demonstrating real potential in Parkinson disease and may have neuroprotective effects through reduced neuroinflammation and improved metabolic signaling. Clinicians are watching several ongoing Phase 3 trials that could establish GLP-1s as neurological treatments within the next few years.
Read full story →Oral GLP-1 Pills Are Reshaping Obesity Care and Medical Training, AAMC Analysis Finds
TLDR: The Association of American Medical Colleges examines how FDA-approved oral GLP-1 pills from Novo Nordisk and Eli Lilly are lowering the injection-aversion barrier and shifting obesity management toward primary care. Medical schools are updating residency curricula as GLP-1 prescribing moves from specialist territory to a routine competency expected of all clinicians.
Read full story →Wednesday — Wednesday, April 22, 2026
5 articlesFDA Compounding Deadline Hits Today: Small 503A Pharmacies Must Stop Producing Semaglutide
TLDR: April 22 marks the FDA enforcement deadline for state-licensed 503A compounding pharmacies to halt production of semaglutide, with larger 503B outsourcing facilities given until May 22 to wind down. The phased shutdown closes a loophole that flourished during the shortage and is expected to push price-sensitive patients toward branded Wegovy and Ozempic, telehealth weight-loss programs, or oral alternatives like the newly approved Foundayo.
Read full story →Mass General Brigham Real-World Study Finds Tirzepatide and Semaglutide Both Cut Heart Attack and Stroke Risk
TLDR: An analysis of nearly one million adults published in Nature Medicine found semaglutide cut the combined risk of heart attack and stroke by 18 percent versus sitagliptin, while tirzepatide produced a 13 percent reduction in major cardiovascular events versus dulaglutide. Head-to-head, the two drugs delivered comparable cardioprotection, reinforcing both as foundational options for patients with type 2 diabetes and elevated cardiometabolic risk.
Read full story →Lilly Foundayo Now Shipping Through LillyDirect and Retail Pharmacies After FDA Nod for Oral GLP-1 Pill
TLDR: Foundayo (orforglipron), the first once-daily oral GLP-1 that can be taken any time of day without food or water restrictions, is now shipping nationwide through LillyDirect and rolling out across retail pharmacies and telehealth providers. Commercial-insured patients can pay $25 a month with the Lilly savings coupon, while cash payers face $149 to $349 depending on dose, opening a lower-friction onramp for patients who have avoided injectables.
Read full story →Medicare GLP-1 Bridge to Cap Wegovy, Zepbound, and Foundayo Copays at $50 Starting July 1
TLDR: CMS confirmed the Medicare GLP-1 Bridge will launch July 1 and run through December 2027, capping Part D copays at $50 for Foundayo, Wegovy injection and tablets, and Zepbound for eligible obesity patients. The temporary program bridges the gap until the broader BALANCE Model expands GLP-1 coverage in Medicaid in May 2026 and Medicare Part D in January 2027.
Read full story →Stanford Researchers Identify Genetic GLP-1 Resistance That May Explain Why Drugs Fail in 1 in 10 Patients
TLDR: A new Stanford-led study in Genome Medicine pinpointed gene variants that may explain why roughly 10 percent of patients see little response to Ozempic, Wegovy, and similar GLP-1 receptor agonists. The patients show elevated endogenous GLP-1 hormone levels but blunted receptor signaling, hinting at a future where genetic screening guides who is likely to benefit from injectable GLP-1s versus alternative therapies.
Read full story →Tuesday — Tuesday, April 21, 2026
5 articlesLilly's Employer Connect Picks Up Steam as Benefits Consultants Weigh GLP-1 Coverage Playbook
TLDR: Benefits consultants are urging employers to revisit their GLP-1 coverage strategies now that Lilly's Employer Connect platform is live with more than fifteen program administrators, including GoodRx, Teladoc Health and Mark Cuban Cost Plus Drug Company. The platform offers Zepbound at a fixed $449 per month net price, less than half the list price, but the piece warns that plan sponsors still need to pair it with utilization management and eligibility rules to avoid runaway spend.
Read full story →Secret Shopper Study Finds Many Weight-Loss Clinics Selling Compounded GLP-1s With Opaque Sourcing
TLDR: Researchers interviewed 75 weight-loss clinics and spas advertising compounded GLP-1s and found widespread use of additives, inconsistent sterile compounding licensure, and four facilities with recent state board or FDA disciplinary actions. Of 58 sites that answered a question about additives, 44 said they had such products on hand, and only 17 of 21 traditional 503A pharmacies were licensed for sterile compounding.
Read full story →Employers Get Creative With GLP-1 Cost Controls as Obesity Drug Spend Strains Health Budgets
TLDR: Self-funded employers are layering prior authorization, lifestyle program prerequisites, BMI cutoffs and shared-risk contracts with vendors to keep GLP-1 budgets from ballooning, with some reporting monthly spend per treated employee still north of one thousand dollars. Seventy-seven percent of employers with 500 or more workers now rank GLP-1 cost management as extremely or very important, and a growing share have pulled weight-loss coverage altogether after earlier experiments with open access.
Read full story →APhA2026: Pharmacists Told GLP-1s Are Rewriting the Rules of Metabolic Disease Management
TLDR: Clinicians at the American Pharmacists Association 2026 meeting told attendees that GLP-1 therapy is now a foundational tool across type 2 diabetes, obesity, cardiovascular disease, chronic kidney disease and obstructive sleep apnea, and that pharmacists should expect a steady stream of new indications through the next two years. Speakers emphasized the emerging role of oral GLP-1s and urged counseling on adherence, gastrointestinal side effects and muscle preservation to match the new generation of pill-based therapies.
Read full story →Liver Researchers Pinpoint How GLP-1 Drugs Quiet Inflammation Even Without Weight Loss
TLDR: A new line of research highlighted by liver specialists identifies a subset of liver cells that, once stimulated by GLP-1, signal the immune system to turn down inflammation, offering a mechanistic explanation for why patients who lose little weight can still see lower cardiovascular and liver event rates on semaglutide or tirzepatide. Clinicians say the findings strengthen the case for thinking of GLP-1s as cardiometabolic drugs that happen to cause weight loss, rather than the other way around.
Read full story →Monday — Monday, April 20, 2026
5 articlesSemaglutide May Preserve More Lean Muscle Than Tirzepatide, Preprint Analysis Suggests
TLDR: A new observational analysis posted on medRxiv found that patients on tirzepatide lost about 56 percent more lean muscle than those on semaglutide, despite losing 57 percent more total weight. Researchers cautioned the findings are preliminary and have not yet been peer reviewed, but the body composition signal could reshape how clinicians weigh the two GLP-1 drugs against each other.
Read full story →GLP-1 Drugs Linked to 15 Percent Lower Heart Risk and 19 Percent Lower Kidney Failure Risk in Type 1 Diabetes
TLDR: An analysis of roughly 175,000 adults with type 1 diabetes found that those taking GLP-1 receptor agonists such as semaglutide or tirzepatide had a 15 percent lower five-year risk of major cardiovascular events and a 19 percent lower risk of end-stage kidney disease. The data add to a growing body of evidence that the drugs' benefits reach beyond weight loss and type 2 diabetes.
Read full story →New Study Finds Wegovy Carries Higher Vision Loss Risk Than Ozempic
TLDR: A study published in the British Journal of Ophthalmology reported that patients on Wegovy had a vision loss risk nearly five times higher than those on Ozempic, even though both semaglutide formulations were associated with an increased signal for eye complications. The authors stopped short of recommending changes to prescribing, but called for closer ophthalmic monitoring in high-risk patients.
Read full story →Roughly 10 Percent of Patients May Be Genetically Resistant to GLP-1 Drugs, Study Finds
TLDR: Research published in Genome Medicine identified genetic variants that appear to blunt the blood sugar response to GLP-1 drugs in about one in ten patients. The affected individuals produced higher levels of the hormone the drugs target but did not respond normally to it, a pattern the authors describe as GLP-1 resistance. The findings could eventually help clinicians predict who is unlikely to benefit from Ozempic or Wegovy.
Read full story →FDA Warns Patients About Counterfeit Ozempic and Unapproved Ingredients in Online GLP-1 Ads
TLDR: Consumer coverage this month revisited the FDA's ongoing warnings about counterfeit Ozempic and non-approved ingredients turning up in compounded GLP-1 products sold online. Regulators urged patients to verify pharmacy credentials and prescribers before purchasing, and warned that cut-rate ads promising rapid weight loss often mask unverified supply chains.
Read full story →Sunday — Sunday, April 19, 2026
4 articlesLilly's ACHIEVE-4 Trial: Foundayo Cuts All-Cause Mortality 57% vs. Insulin Glargine
TLDR: Lilly's longest Phase 3 study of orforglipron (Foundayo) met its primary non-inferiority endpoint for major cardiovascular events against insulin glargine in more than 2,700 patients with type 2 diabetes and cardiovascular risk, and showed a 57 percent lower risk of all-cause death in the Foundayo arm. At 52 weeks patients on Foundayo lost 8.8 percent of body weight versus a 1.7 percent gain on insulin. Lilly plans to submit Foundayo for type 2 diabetes to the FDA by the end of Q2.
Read full story →Foundayo Debut Week Lands 1,390 Prescriptions, Trailing Novo's Oral Wegovy Launch
TLDR: Foundayo, the second oral GLP-1 approved for weight loss, logged about 1,390 prescriptions in its first week on the market through April 10, running well behind the roughly 3,071 scripts Novo Nordisk's oral Wegovy posted over four days after its January launch. Analysts still see Foundayo as a blockbuster, with some forecasting more than five million prescriptions in 2026 as telehealth partners and retail distribution come online. Pricing runs $25 per month with commercial coverage and $149 per month self-pay.
Read full story →Penn AI Study of 400,000 Reddit Posts Flags Underreported GLP-1 Side Effects
TLDR: University of Pennsylvania researchers used a large language model to scan more than 400,000 Reddit posts from nearly 70,000 GLP-1 users and found patient-reported symptoms that rarely surface in clinical trial data, including fatigue, chills, menstrual irregularities and psychiatric effects. Fatigue ranked second behind nausea at 16.7 percent of reports, and roughly 4 percent of posts described reproductive changes such as intermenstrual and heavy bleeding. The authors stress the signals are hypothesis-generating and need prospective confirmation, but argue they point to gaps in current post-market surveillance.
Read full story →Ozempic GLP-1 MDL Swells to 3,546 Cases as NAION Vision-Loss Docket Takes Shape
TLDR: The federal Ozempic multidistrict litigation added 183 new cases between March and April, bringing the gastroparesis and bowel-injury MDL 3094 to 3,546 pending lawsuits, while a separate NAION vision-loss docket (MDL 3163) grew to 73 cases under the same judge. About 75 percent of complaints allege gastroparesis or stomach paralysis, with smaller subsets citing ileus, gallbladder injury and permanent vision loss. No global settlement or bellwether trials have been scheduled as of April 2026.
Read full story →Saturday — Saturday, April 18, 2026
4 articlesGLP-1 Pioneers Propose New Weight-Loss Approach That Skips GLP-1 Entirely
TLDR: Two scientists whose early work spawned today's GLP-1 drugs — Richard DiMarchi and Matthias Tschoep — published findings arguing that activating GIP and glucagon receptors at high enough doses can match GLP-1-level weight loss without the nausea and vomiting that drive many patients off treatment. Their experimental compound produced comparable results to leading obesity drugs in monkeys and rodents, and the authors now say targeting GLP-1 itself may not be necessary. Human studies are the next step.
Read full story →Even When GLP-1s Do Not Drive Weight Loss, Patients May Still See Organ Benefits
TLDR: New research suggests GLP-1 drugs protect the liver, heart, and kidneys through pathways that do not depend on shedding pounds. A University of Toronto team identified liver blood-vessel cells that, when triggered by GLP-1, quiet inflammation regardless of weight change — a finding that could push insurers to rethink policies that tie coverage to a minimum weight-loss threshold.
Read full story →GLP-1 Patients Are Spending 55% More on Fresh Produce, Survey Finds
TLDR: A new consumer survey from the Acosta Group reports that GLP-1 users are spending 55% more on fresh produce than before starting treatment, alongside sharp increases in yogurt, fresh chicken, and protein products, and noticeable cuts in sweets, salty snacks, and sugary drinks. About half of respondents said the shift changed their entire household's eating habits — a figure that climbed to 79% among millennials.
Read full story →FDA Tightens Grip on Compounded GLP-1s With April 1 Policy Clarification
TLDR: The FDA used a rare April 1 statement to remind 503A pharmacies and 503B outsourcing facilities that semaglutide and tirzepatide remain off the bulk-drug and shortage lists, meaning compounded versions only qualify for exemption under narrow conditions. The agency flagged combination formulations — such as semaglutide plus vitamin B12 — as likely copies of approved drugs, and signaled stepped-up enforcement against mass-marketed compounded products.
Read full story →Friday — Friday, April 17, 2026
4 articlesScientists Discover "GLP-1 Resistance" Explains Why Ozempic Fails for Some Patients
TLDR: A new study has identified genetic variants that cause roughly 10% of patients to be resistant to GLP-1 medications like Ozempic and Wegovy. These individuals produce higher levels of GLP-1 naturally but their bodies fail to respond to it, potentially explaining why the drugs show limited efficacy for some users.
Read full story →Quitting and Restarting GLP-1 Drugs: What Doctors Want Patients to Know
TLDR: With fewer than 1 in 4 patients staying on GLP-1 medications after a year, many are cycling on and off these drugs. Doctors caution that stopping and restarting is not recommended, as patients often regain weight rapidly and may face different side effects upon resumption.
Read full story →Digital Health Companies Pivot to Integrate GLP-1 Prescribing with Long-Term Metabolic Care
TLDR: A new analysis shows digital health platforms are rapidly evolving beyond simple coaching to offer full-service GLP-1 care coordination, including prescription management, monitoring, and long-term metabolic support. The shift reflects growing recognition that medication alone is insufficient without sustained behavioral intervention.
Read full story →GLP-1 Market Projected to Reach $66.5 Billion by 2035 as Access Expands
TLDR: New market projections estimate the global obesity GLP-1 market will grow from $10.12 billion in 2026 to $66.57 billion by 2035, driven by reduced drug prices, Medicare coverage set to begin in July, and the recent FDA approval of oral GLP-1 options like Eli Lilly's Foundayo.
Read full story →Thursday — Thursday, April 16, 2026
5 articlesMany Patients Quit GLP-1s Within a Year, and Restarting Carries Hidden Risks
TLDR: Fewer than 1 in 4 patients remain on a GLP-1 medication after 12 months, and clinicians are warning that stopping and restarting the drugs is not without consequences. As much as 40 percent of weight lost on GLP-1s is lean muscle, and rebound weight gain plus repeated cycles of dose escalation can amplify side effects and muscle loss.
Read full story →Johns Hopkins Study: GLP-1s Cut Cardiovascular and Kidney Events in Type 1 Diabetes
TLDR: A new Johns Hopkins-led analysis found that adults with type 1 diabetes who took GLP-1 receptor agonists had roughly a 15 percent lower five-year risk of major cardiovascular events and a 19 percent lower risk of end-stage kidney disease versus non-users. The study also reported estimated risk reductions of 18 percent for heart failure and 28 percent for major adverse liver events, with no new safety signals.
Read full story →Eli Lilly Pulls Further Ahead of Novo Nordisk in the GLP-1 Arms Race
TLDR: Analysts point to Eli Lilly's broader obesity pipeline, including newly approved oral GLP-1 Foundayo and late-stage triple-agonist retatrutide, as the main reason its valuation has separated from Novo Nordisk's. Retatrutide posted a 28.7 percent mean weight loss at the highest dose in a 68-week phase 3 study while also easing knee osteoarthritis pain, raising the bar for next-generation obesity drugs.
Read full story →Experts Push Back on Viral Claim That Retatrutide Makes Users "Fall Out of Love"
TLDR: Social media posts claiming Eli Lilly's experimental triple-agonist retatrutide dampens romantic attachment by acting on dopamine and reward pathways are spreading, but clinicians say the idea is theoretical and unsupported by current data. No published trial has measured mood, libido, or relationship outcomes as endpoints, and reported mental health changes on GLP-1s remain rare and inconsistent.
Read full story →Neurologists Weigh Repurposing GLP-1 Drugs for Alzheimer's, Parkinson's and Addiction
TLDR: A growing body of trial data is being reviewed on the use of GLP-1 receptor agonists in Alzheimer's disease, Parkinson's disease, stroke recovery and substance use disorders. Clinicians caution that most neurologic indications remain investigational, but early signals on neuroinflammation and cravings are prompting larger confirmatory studies.
Read full story →Wednesday — Wednesday, April 15, 2026
5 articlesFDA Requests Additional Safety Data From Lilly on Foundayo Weight-Loss Pill
TLDR: The FDA is asking Eli Lilly to gather more post-marketing safety data on Foundayo (orforglipron), its recently approved oral GLP-1 weight-loss pill. Regulators flagged incomplete evidence on potential cardiovascular risks including heart attack and stroke as well as possible drug-induced liver injury.
Read full story →Emerging Evidence Suggests GLP-1 Drugs Help Even Patients Who Do Not Lose Weight
TLDR: New research published this week adds to a growing body of evidence that GLP-1 medicines deliver cardiovascular, liver, and metabolic benefits independent of weight loss. Clinicians note that 10 to 15 percent of patients are weight-loss non-responders, yet many still see meaningful improvements in liver fat, blood pressure, and glycemic control.
Read full story →Researchers Identify Genetic Variants Behind Ozempic Non-Response
TLDR: Scientists report that roughly 10 percent of patients taking semaglutide carry genetic variants that blunt response to GLP-1 therapy, a phenomenon being described as GLP-1 resistance. Affected individuals appear to produce higher endogenous GLP-1 but show reduced receptor signaling, which may explain inconsistent weight-loss outcomes.
Read full story →CVS Formulary Switch Drove Sharp Shift From Tirzepatide to Semaglutide, Truveta Analysis Finds
TLDR: A Truveta Research analysis presented at AMCP 2026 found that after CVS Caremark made anti-obesity semaglutide its preferred formulary option in July 2025, tirzepatide-to-semaglutide switching jumped from 0.6 percent to 9.7 percent of patients, with roughly 80 percent of switchers moving to semaglutide for obesity.
Read full story →Doctors Warn of Rising Unsupervised GLP-1 Use and Muscle Loss Risk
TLDR: As GLP-1 prescribing expands globally, physicians are flagging a surge in unsupervised use driven by compounded products and online pharmacies. Clinicians warn of sarcopenia, nutritional deficiencies, and rebound weight gain when patients take GLP-1s without structured monitoring or protein and resistance-training support.
Read full story →Tuesday — Tuesday, April 14, 2026
5 articlesCMS Adds Foundayo to Medicare GLP-1 Bridge Ahead of July 1 Launch
TLDR: CMS updated its Medicare GLP-1 Bridge program on April 6 to include Eli Lilly's newly approved Foundayo (orforglipron). Beginning July 1, eligible Medicare beneficiaries will pay $50 per month for Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound through December 31, 2026.
Read full story →Johns Hopkins: GLP-1 Drugs Cut Cardiovascular and Kidney Risk in Type 1 Diabetes Patients
TLDR: Analyzing electronic health records from about 175,000 U.S. patients, Johns Hopkins researchers found type 1 diabetes patients on GLP-1 receptor agonists had a 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease. The findings could expand off-label GLP-1 use in T1D.
Read full story →Stanford Study Identifies Genetic 'GLP-1 Resistance' Affecting Roughly 10% of Patients
TLDR: A Stanford Medicine-led study published in Genome Medicine found that specific genetic variants leave roughly 10% of people with elevated GLP-1 levels but blunted response to drugs like Ozempic and Wegovy. The work helps explain why some patients see little weight loss despite adherence and points toward future genetic screening.
Read full story →Eli Lilly's Foundayo Oral GLP-1 Now Shipping Nationwide via LillyDirect
TLDR: Foundayo (orforglipron), Eli Lilly's once-daily oral GLP-1 approved April 1, began shipping to U.S. patients this week. Cash-pay prices range from $149 to $349 per month depending on dose, with Lilly discount cards offering insured patients access starting at $25 per month. Unlike Wegovy's pill, Foundayo can be taken any time, with or without food.
Read full story →New Study Shows Cardiovascular Benefit of GLP-1s in Women with Type 2 Diabetes and Breast Cancer
TLDR: A real-world analysis published in Pharmacotherapy found GLP-1 receptor agonists were associated with improved cardiovascular outcomes in women with type 2 diabetes who are breast cancer survivors. The findings add to growing evidence supporting GLP-1 use in cancer survivor populations with elevated cardiometabolic risk.
Read full story →Monday — Monday, April 13, 2026
7 articlesGLP-1 Pills Outpace Injectable Adoption With 170,000 Prescriptions in First Two Months
TLDR: The new oral GLP-1 weight-loss pills have been prescribed to roughly 170,000 people since launch, outpacing the early adoption rate of injectable versions like Wegovy and Zepbound.
Read full story →CMS BALANCE Model on Track for May Medicaid Launch, Expanding GLP-1 Access
TLDR: The BALANCE Model, which allows Medicaid and Medicare Part D plans to cover GLP-1 medications for weight management, remains on track for a May 2026 Medicaid launch and January 2027 Medicare rollout.
Read full story →Researchers Explore GLP-1 Drugs for Heart Failure, Liver Disease, and Substance Use Disorders
TLDR: Scientists are investigating GLP-1 medications for conditions beyond obesity and diabetes, including heart failure, chronic liver disease, obstructive sleep apnea, and substance use disorders, with multiple clinical trials underway.
Read full story →Tirzepatide Beats Semaglutide in 12-Month Real-World Weight Loss Study
TLDR: A real-world analysis of US adults with obesity using the Truveta electronic health records database found tirzepatide patients were significantly more likely to hit weight-loss thresholds of 10%, 15%, 20%, and 25% at 12 months versus semaglutide. Results were presented at the Obesity Medicine Association annual meeting in San Diego.
Read full story →Stanford Researchers Identify BRP, a Natural Molecule That Curbs Appetite Like Ozempic
TLDR: Stanford scientists described a newly identified molecule called BRP that appears to mimic the appetite-suppressing effects of GLP-1 drugs by acting directly on the brains appetite-control center. In animal studies, BRP reduced food intake and fat mass without the nausea or muscle loss often seen with current GLP-1 medications.
Read full story →Study Suggests Roughly 10% of Patients May Have GLP-1 Resistance
TLDR: New research points to a hidden reason Ozempic and similar drugs fail for some patients: about 10% of people appear to have a form of GLP-1 resistance, producing higher levels of the hormone these drugs target but responding poorly to it. The finding could help explain non-responders and guide future drug development.
Read full story →Physicians Warn Against Unsupervised GLP-1 Use as Demand Surges
TLDR: Clinicians are flagging a rise in patients self-prescribing GLP-1 drugs without medical oversight, citing risks of muscle loss, nutritional deficiencies, and long-term metabolic complications. Doctors are urging that GLP-1 therapy be paired with supervised nutrition, resistance training, and lab monitoring.
Read full story →Sunday — Sunday, April 12, 2026
3 articlesStanford Scientists Discover "Natural Ozempic" Molecule That Avoids Common Side Effects
TLDR: Stanford researchers identified a naturally occurring peptide called BRP that acts directly on the brain's appetite center. In animal studies it matched Ozempic's weight-loss effects while avoiding nausea, constipation, and muscle loss. Human trials are planned.
Read full story →Amazon Pharmacy Begins Same-Day Delivery of Lilly's Foundayo GLP-1 Pill
TLDR: Amazon Pharmacy launched same-day delivery of Foundayo (orforglipron) in nearly 3,000 cities, with plans to expand to 4,500 by year-end. The oral GLP-1 pill costs $25/month with insurance or $149/month cash pay.
Read full story →Medicare GLP-1 Bridge Program Updated to Include Foundayo
TLDR: CMS updated its Medicare GLP-1 Bridge program to include Eli Lilly's newly approved Foundayo alongside Wegovy and Zepbound, offering eligible Part D beneficiaries access at a $50/month copay.
Read full story →Saturday — Saturday, April 11, 2026
7 articlesLifeMD Now Prescribing Eli Lilly's Foundayo Pill Through Its Telehealth Platform
TLDR: LifeMD announced it is now offering Eli Lilly's Foundayo (orforglipron), the newly FDA-approved oral GLP-1 pill, through its telehealth weight-management platform. The move makes LifeMD one of the first major telehealth providers to prescribe the drug, expanding patient access beyond LillyDirect and traditional pharmacies.
Read full story →AI-Based Monitoring Reveals Widespread Protein Deficiencies in GLP-1 Users
TLDR: A new study using AI-based dietary monitoring found that 88% of patients taking semaglutide or tirzepatide for weight loss fall below recommended daily protein intake. Researchers warn that the significant calorie reduction caused by GLP-1 drugs leaves users vulnerable to muscle loss and nutritional deficiencies without proactive dietary guidance.
Read full story →First Indian Cohort Study Finds Mounjaro Outperforms Ozempic for Weight Loss
TLDR: The first study comparing GLP-1 drugs in Indian patients found tirzepatide (Mounjaro) users lost a median 8.6% of body weight versus 5.6% for semaglutide (Ozempic/Wegovy) users. Nearly half of tirzepatide patients crossed the 10% weight loss threshold, compared to just 21% on semaglutide.
Read full story →Eli Lilly's Oral GLP-1 Could Reshape the Obesity Drug Market, Analysts Say
TLDR: Market analysts say Foundayo's lack of food and water restrictions gives it a meaningful convenience edge over Novo Nordisk's oral Wegovy, which requires an empty stomach and a 30-minute wait before eating. With Novo already reporting over 600,000 oral Wegovy prescriptions, the oral GLP-1 segment is quickly becoming the primary battleground in obesity treatment.
Read full story →Study Reveals 10% of People May Have "GLP-1 Resistance" Due to Genetic Variants
TLDR: A Stanford-led study published in Genome Medicine found that variants in the PAM gene may cause GLP-1 resistance in roughly 1 in 10 people, potentially explaining why drugs like Ozempic and Wegovy are less effective for some patients.
Read full story →Large Genetic Study Links DNA Variants to GLP-1 Weight Loss Outcomes and Side Effects
TLDR: A 23andMe-backed analysis of nearly 28,000 people identified a GLP1R gene variant associated with greater weight loss on GLP-1 medications, and a GIPR variant linked to nausea specifically in tirzepatide users.
Read full story →Foundayo Now Available Through Telehealth Providers Nationwide
TLDR: Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) is now available through LillyDirect and multiple telehealth platforms, expanding access to the $149/month weight-loss pill approved April 1.
Read full story →Friday — Friday, April 10, 2026
4 articlesFoundayo Hits U.S. Retail Pharmacies as Eli Lilly Ramps Up Oral GLP-1 Distribution
TLDR: Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) is now available at retail pharmacies nationwide, just over a week after FDA approval. The drug shipped via LillyDirect starting April 6 and reached brick-and-mortar pharmacies by April 9, priced at $149 per month self-pay or $25 with commercial insurance.
Read full story →Generic Semaglutide Surge in India Dents Eli Lilly's Mounjaro Sales
TLDR: Cheap generic semaglutide copies flooding the Indian market after Novo Nordisk's local patent expired have cut into Eli Lilly's Mounjaro sales, which fell to 1.14 billion rupees in March from 1.35 billion in February. Generic semaglutide's market share jumped to 33% from 25% in one month, with prices as low as $14 per month.
Read full story →Novo Nordisk Reports Wegovy Pill Is Drawing First-Time GLP-1 Patients, Not Cannibaling Injections
TLDR: Novo Nordisk says oral Wegovy is primarily attracting patients who never tried injectable GLP-1s rather than switching existing users, expanding the total addressable market. The company has surpassed 600,000 prescriptions since the pill's December launch, making it the most successful obesity drug launch ever.
Read full story →Survey: Americans Overwhelmingly Prefer GLP-1 Pills Over Injections for Cost and Convenience
TLDR: A new survey finds that Americans starting weight-loss medications strongly prefer oral GLP-1 options over injectables, citing lower cost and greater convenience as the top factors. The findings come as both Wegovy's pill and Foundayo compete for first-time patients in a rapidly expanding market.
Read full story →Thursday — Thursday, April 9, 2026
4 articlesNature Study Identifies Genetic Variants That Predict How Well GLP-1 Drugs Work
TLDR: A 23andMe Research Institute genome-wide study of 27,885 GLP-1 users, published April 8 in Nature, identified a GLP1R variant (rs10305420) that predicts greater weight loss on semaglutide or tirzepatide and a GIPR variant (rs1800437) linked to worse nausea specifically in tirzepatide users. The findings suggest genetic testing could eventually help tailor obesity treatment for the roughly 1 in 4 patients who respond poorly.
Read full story →CMS Adds Foundayo to Medicare GLP-1 Bridge, Clarifies Zepbound Coverage
TLDR: CMS updated the Medicare GLP-1 Bridge on April 6 to include Eli Lilly's newly approved Foundayo (orforglipron) alongside Wegovy and to clarify that only the Zepbound KwikPen formulation is eligible. Starting July 1, eligible Part D beneficiaries will be able to obtain covered GLP-1 drugs for weight reduction with a $50 copayment through the end of 2026.
Read full story →Johns Hopkins Study: GLP-1 Drugs Work Comparably Across Age, Race, and Starting Weight
TLDR: A new Johns Hopkins analysis found that semaglutide and tirzepatide produced similar percentage weight loss across patients of different ages, races, and baseline weights in real-world use, pushing back on concerns that the drugs work less well for some demographic groups. The researchers say prescribing decisions should focus on access and tolerability rather than demographic predictors.
Read full story →Foundayo Price Matching Tempers Lilly Stock Gains as Novo Wegovy Pill Rivalry Heats Up
TLDR: Eli Lilly's share price reaction to last week's Foundayo approval has cooled as analysts digest aggressive price matching with Novo Nordisk's oral Wegovy. Foundayo launches at $149 per month self-pay (up to $349 at higher doses) and $25 with commercial insurance, mirroring Wegovy pill pricing and signaling that the oral GLP-1 market will be fought on price as much as efficacy.
Read full story →Wednesday — Wednesday, April 8, 2026
4 articlesAnalysts Project Blockbuster Year for Foundayo, Floating 5 Million Prescriptions in 2026
TLDR: UBS analysts say Eli Lilly needs roughly 5.4 million Foundayo prescriptions from April through December to hit the $1.7 billion consensus sales estimate. Brokerages project 2026 revenue ranging from $1.5 billion to $2.8 billion, with RBC forecasting peak annual sales above $36 billion.
Read full story →FDA Adverse Event Data Reveal Distinct Safety Profiles Across Five Major GLP-1 Drugs
TLDR: A retrospective analysis of the FDA FAERS database from 2012 to 2025 found significant differences in adverse event profiles among GLP-1 medications. Semaglutide was linked to more gastrointestinal and psychiatric events, while dulaglutide and exenatide showed higher rates of death and hospitalization.
Read full story →Researchers Explore GLP-1 Drugs as Potential Treatment for Alzheimer's, Parkinson's, and Other Brain Diseases
TLDR: A growing body of evidence suggests GLP-1 receptor agonists may have neuroprotective effects beyond metabolic benefits. Researchers are investigating their potential to treat Alzheimer's disease, Parkinson's disease, and other neurological conditions through anti-inflammatory and neurotrophic pathways.
Read full story →Next-Gen GLP-1 Pills Expected to Reshape Food and Beverage Industry Demand Patterns
TLDR: Industry analysts say the arrival of convenient oral GLP-1 options like Foundayo and Wegovy's pill will accelerate adoption far beyond injectable users, forcing major shifts in food, beverage, and restaurant demand as millions more consumers reduce calorie intake.
Read full story →Tuesday — Tuesday, April 7, 2026
4 articlesWegovy Pill Launch Draws New Wave of Patients Into GLP-1 Treatment, Expanding the Market
TLDR: Novo Nordisk reports its oral Wegovy pill is attracting first-time GLP-1 patients rather than converting existing injection users, expanding the total addressable market for obesity treatment.
Read full story →Medicare Insurers Face Billions in Costs Under Trump Weight-Loss Drug Proposal
TLDR: Bloomberg estimates the CMS Medicare GLP-1 Bridge program could cost Part D insurers billions annually, with Foundayo, Wegovy, and Zepbound available to eligible beneficiaries at reduced prices starting July 1.
Read full story →FDA Compounding Deadline Leaves Millions Scrambling as Enforcement Ramps Up
TLDR: The FDA final compliance deadline barred most compounding pharmacies from producing semaglutide copies, affecting 3-4 million patients. Pharmacy groups fight back in court.
Read full story →How Eli Lilly Foundayo Stacks Up Against Wegovy and Other Weight-Loss Drugs
TLDR: Scientific American compares Foundayo with oral Wegovy and injectables. Foundayo offers dosing flexibility but its 12% weight loss trails injectable options.
Read full story →Sunday — Sunday, April 5, 2026
6 articlesFDA Approves Eli Lilly's Foundayo (Orforglipron), First GLP-1 Pill With No Food or Water Restrictions
TLDR: The FDA approved Foundayo, Eli Lilly's once-daily oral GLP-1 for obesity, making it the second GLP-1 pill on the market. Unlike the Wegovy pill, Foundayo can be taken any time of day without food or water restrictions. Trial participants on the highest dose lost an average of 12% body weight over 72 weeks.
Read full story →Wegovy HD (Semaglutide 7.2 mg) Approved Under FDA's New Fast-Track Program With 20.7% Weight Loss
TLDR: The FDA approved Wegovy HD, a higher-dose 7.2 mg semaglutide injection, in just 54 days under the new Commissioner's National Priority Voucher program. The STEP UP trial showed 20.7% mean weight loss in adults with obesity, the strongest result yet for a single-agent GLP-1.
Read full story →UK Drug Regulator Clears Wegovy for Heart Disease Prevention, Expanding NHS Access to 1.2 Million People
TLDR: England's NICE recommended Wegovy for reducing the risk of major cardiovascular events in adults who have previously had a heart attack, stroke, or serious circulatory problem. The decision expands NHS access by approximately 1.2 million people beyond current weight-loss indications.
Read full story →Tirzepatide Outperforms Dulaglutide in Reducing Heart and Kidney Risks in SURPASS-CVOT Data
TLDR: New data from the SURPASS-CVOT trial show tirzepatide reduced major adverse cardiovascular and kidney events by 16% compared to dulaglutide. Death from any cause occurred in 8.6% of tirzepatide patients versus 10.2% on dulaglutide.
Read full story →Pfizer's Once-Monthly GLP-1 Injection Shows Continued Weight Loss With No Plateau in Phase 2b Trial
TLDR: Pfizer reported positive Phase 2b results for PF-3944, an ultra-long-acting GLP-1 that requires only monthly dosing. Weight loss continued after switching from weekly to monthly injections with no plateau observed at 28 weeks. Pfizer plans to advance 10 Phase 3 trials this year.
Read full story →GLP-1 Weight Loss Drugs Equally Effective Across Age, Race, and Starting Weight, Johns Hopkins Study Finds
TLDR: A Johns Hopkins study found GLP-1 medications work similarly well regardless of patient age, race, or starting weight. Women lost about 11% of starting weight compared to 7% for men, but the drugs showed consistent effectiveness across all demographic groups studied.
Read full story →Saturday — Saturday, April 4, 2026
4 articlesNovo Nordisk Fires Back: Claims Wegovy Pill Outperforms Lilly's Foundayo in Weight Loss
TLDR: Novo Nordisk responded to Foundayo's approval by releasing cross-trial data showing oral Wegovy achieved 16.6% average weight loss versus Foundayo's 12.4%. However, analysts note the comparison is imperfect since the drugs were not tested head-to-head, and Foundayo's advantage of no food or water restrictions may drive stronger patient adherence.
Read full story →Trump's Medicare GLP-1 Plan Would Cost Insurers Billions, Bloomberg Analysis Finds
TLDR: A Bloomberg analysis estimates that the administration's plan to cover GLP-1 weight loss drugs under Medicare Part D would cost insurers billions annually. The CMS BALANCE Model launching in July 2026 at $50 per month per beneficiary is expected to drive massive enrollment, raising questions about long-term program sustainability.
Read full story →Foundayo Prescriptions Now Open, First Shipments Begin April 6
TLDR: Eli Lilly began accepting prescriptions for Foundayo through LillyDirect, with shipping starting April 6 and broad retail pharmacy availability to follow. Eligible patients with commercial insurance can pay as little as $25 per month with a savings card, while self-pay starts at $149 per month for the lowest dose.
Read full story →FDA Warns Novo Nordisk Over Misleading Ozempic Television Advertisement
TLDR: The FDA issued a warning letter to Novo Nordisk stating that a recent Ozempic TV ad contained false or misleading claims suggesting superiority over other GLP-1 diabetes drugs. The agency cited violations of the Federal Food, Drug, and Cosmetic Act for overstating efficacy without adequate risk disclosure.
Read full story →Friday — Friday, April 3, 2026
4 articlesEli Lilly's Foundayo Pill Approved by FDA — No Food or Water Restrictions Required
TLDR: The FDA approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for weight loss, which can be taken any time of day without food or water restrictions. It is the first new molecular entity approved under the National Priority Voucher program, with the review completed in just 50 days. Available starting at $149/month out of pocket.
Read full story →Novo Nordisk Says Oral Wegovy Now Broadly Available Across America
TLDR: Novo Nordisk announced that the oral version of Wegovy, the first FDA-approved GLP-1 pill for weight loss, is now broadly available at pharmacies nationwide. The pill competes directly with Lilly's newly approved Foundayo, though it requires morning dosing on an empty stomach.
Read full story →GLP-1 Drugs Reshaping U.S. Retail Spending Patterns, New Analysis Finds
TLDR: An analysis of nearly 96,000 GLP-1 consumer conversations reveals how medication adoption is restructuring U.S. retail demand, with shifts in food, fitness, and apparel purchasing patterns that retailers are failing to anticipate.
Read full story →Commercial Insurance Coverage for GLP-1 Weight Loss Drugs Shrinks in 2026
TLDR: The number of people without commercial insurance coverage for Wegovy jumped 42% compared to 2025, leaving over 41 million uninsured for the drug. Over 88% of those with coverage still face prior authorization hurdles, even as Medicare prepares to expand access through the BALANCE Model starting mid-2026.
Read full story →Thursday — Thursday, April 2, 2026
4 articlesFDA Approves Eli Lilly's Foundayo Pill, Second Oral GLP-1 for Obesity
TLDR: The FDA approved Eli Lilly's orforglipron pill Foundayo for obesity, the second oral GLP-1 after Novo Nordisk's Wegovy pill. Unlike Wegovy's pill, Foundayo can be taken anytime without food or water restrictions. Pricing ranges from $149 to $349 per month out of pocket, with a $25 copay option for insured patients.
Read full story →Novo Nordisk Defends Obesity Pill Lead as Lilly's Foundayo Enters Market
TLDR: Eli Lilly's Foundayo approval ends Novo Nordisk's brief monopoly on oral GLP-1 obesity drugs. Novo's Wegovy pill has generated over 600,000 prescriptions since its December approval, but Foundayo's no-fasting convenience and competitive pricing could reshape market dynamics.
Read full story →Top Health Official Predicts GLP-1 Price Crash Could Restore Insurance Coverage
TLDR: A Massachusetts health official predicted a major price crash in GLP-1 medications within two to three years that could lead insurers to restore weight-loss drug coverage. Many commercial plans dropped GLP-1 coverage for obesity in January 2026 due to high costs.
Read full story →FDA Sends 30 New Warning Letters in Escalating Crackdown on Compounded GLP-1s
TLDR: The FDA issued 30 additional warning letters to compounding pharmacies and telehealth firms still selling mass-marketed compounded semaglutide and tirzepatide. With brand-name supply restored, compounded versions are now restricted to rare patient-specific cases with documented medical necessity.
Read full story →Wednesday — Wednesday, April 1, 2026
4 articlesFDA Decision on Eli Lilly Oral GLP-1 Pill Orforglipron Expected April 10
TLDR: The FDA is expected to issue its approval decision on orforglipron, Eli Lilly's once-daily oral GLP-1, by April 10. Phase 3 trials showed the drug achieved up to 12.4% weight loss and outperformed oral semaglutide for blood sugar control. If approved, it would become the second oral GLP-1 for weight management.
Read full story →Wegovy Pill Pricing Shifts: 4 mg Dose Rises to $199 After April 15
TLDR: Novo Nordisk's oral Wegovy is now available at over 70,000 U.S. pharmacies. The introductory $149 monthly price for the 4 mg dose expires April 15 and will increase to $199. The starter 1.5 mg dose remains at $149, while the highest doses will cost $299 per month.
Read full story →Medicare GLP-1 Bridge Program to Launch July 2026 at $50 per Month
TLDR: CMS confirmed its Medicare GLP-1 Bridge demonstration will begin in July 2026, offering eligible beneficiaries GLP-1 medications for $50 per month. The program serves as a precursor to the full BALANCE Model launching in Medicare Part D in January 2027 and Medicaid as early as May 2026.
Read full story →FDA Tightens Enforcement on Compounded Semaglutide as Shortage Officially Ends
TLDR: With injectable semaglutide no longer in shortage, the FDA has ended its enforcement discretion for compounders. Compounded semaglutide is now restricted to rare patient-specific cases with documented medical necessity, and the agency has issued warnings about dangerous impurities found in some compounded products.
Read full story →Tuesday — Tuesday, March 31, 2026
4 articlesBioNxt Advances Semaglutide Oral Dissolving Film as Next-Gen GLP-1 Delivery
TLDR: BioNxt Solutions announced progress on its semaglutide oral dissolving film platform, a sublingual delivery system that could offer faster absorption and easier dosing than current GLP-1 pills. The company is also evaluating expansion to tirzepatide and liraglutide compounds.
Read full story →GLP-1 Patent Cliff Accelerates as Brazil Opens Door to Generic Semaglutide
TLDR: Brazil denied Novo Nordisk's request to extend semaglutide patent protection, opening a major market to generic competition. Combined with patent expirations in China and India, the global GLP-1 generic landscape is shifting rapidly in 2026.
Read full story →CMS Launches BALANCE Model to Expand Medicare and Medicaid GLP-1 Coverage
TLDR: The Centers for Medicare and Medicaid Services launched the BALANCE model to expand GLP-1 access for federal program beneficiaries. Medicare Part D enrollees can expect coverage by July 2026 through a bridge program, with Medicaid BALANCE coverage starting as early as May 2026.
Read full story →Experts Say GLP-1 Drugs Could Transform Global Health But Affordability Remains Critical Barrier
TLDR: Health experts argue that GLP-1 medications have transformative potential for global public health but remain inaccessible to most of the world due to high costs. The call for affordable access is intensifying as patent cliffs approach and generic manufacturers prepare to enter markets worldwide.
Read full story →Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.